The Challenge of Liver Toxicity
in Drug Development.

Testing Limitations (ALT / AST)

Traditional indicators lack specificity and are released by non-hepatic tissues, leading to false safety flags that incorrectly kill viable drug candidates.

PCR's Fatal Flaw: isomiRs

PCR cannot distinguish miRNA variants (isomiRs): degradation products that create false negatives. This renders PCR unreliable for clinical miRNA diagnostics.

$ Billions

Lost opportunities from false positive signals and late-stage failures due to hepatotoxicity

#1

DILI is the leading cause of acute liver failure worldwide

miRNA-122

LiverAce™ Singleplex Kit

Accurate PCR-free miRNA-122 detection

miRNA-122 is well established as an early biomarker for drug-induced liver toxicity from liver organoids, across small and large animal species and in humans. miRNA-122 rises much earlier and is more liver specific than traditional enzymes, such as AST/ALT, providing the high specificity required to eliminate false toxicity flags. By overcoming the miRNA degradation to isomers challenge that plagues the use of PCR for miRNAs, LiverAce™ Singleplex delivers the “Fail-Fast” precision required for confident drug development.

LiverAce Singleplex Kit box – PCR-free miRNA-122 assay for drug-induced liver injury (DILI) on Luminex xMAP by Destina Genomics

For Research Use Only

Not for use in diagnostic procedures

Complete drug development process

Pre-Clinical Phases
Clinical Phases
In Vitro Organoids and Cell Cultures
🐭 🐹
In Vivo Animal Species
👨‍🔬 👩‍🔬
Clinical Human Trials

One assay for the complete drug development process. Provides accurate and reproducible assessment of drug toxicity across all stages, identifying problems early in the development lifecycle.

Diagnostic Sensitivity

Click for Research Details →
LiverAce™ SinglePlex

Key Values

LiverAce Singleplex
Early Detection
isomiR Specificity & Robustness
Highly Liver-Specific
Operational Scalability
Micro-Sampling Requirement
Evidence Base

Scientific Proof

Key Publications (Biomarkers)

Clinical evidence supporting miR-122 as a superior liver injury biomarker.

Destina Chemistry (DGL-Tech)

Foundational papers on the Destina Chemistry that powers LiverAce™ assays.

Technical Specifications

Product Characteristics

Kit Specifications

ParameterValue
AnalytesmiRNA-122
PlatformLuminex xMAP® (MAGPIX®, FLEXMAP 3D®, etc.)
Detection MethodPCR-Free Destina Chemistry
Time to Result< 5 Hours
Sample Volume25 µL
Sample TypeSerum, Plasma
Quantification RangeAbsolute (Calibrators included)

Performance Characteristics

Assay Sensitivity
AnalyteLOD (pg/mL)LLOQ (pg/mL)
miR-1222.48.23
Precision
AnalyteIntra %CVInter %CV
miR-122< 10%< 20%
Workflow

Assay Procedure

Simple, Streamlined, Superior

An immunoassay-like protocol: no RNA extraction and no PCR, so it fits seamlessly into the workflow of any lab already running immunoassays.

1. Add Sample

2. Hybridizing

3. Label

4. Read

Where It Fits

Applications & Research Fields

  • ✓
    Pharma R&D & Drug Development
  • ✓
    CROs & Service Labs
  • ✓
    Preclinical Safety Assessment
  • ✓
    Clinical Trials
  • ✓
    Liver Toxicity (DILI) Screening
Resources

Documentation

Files are available upon request to ensure you receive the latest version.

Product Brochure (PDF)

Ready to Transform Your Liver Safety Assessment?

Our specialists are ready to discuss your testing needs.

Get in Touch